期刊文献+

胃癌中HER-2和GST-π的表达及意义 被引量:2

Expressions and significance of HER-2 and GST-π in human gastric carcinoma
下载PDF
导出
摘要 目的:探讨胃癌组织中人表皮生长因子受体-2(HER-2)和胎盘型谷胱甘肽-S-转移酶-π(GST-π)的表达及与临床病理特征的关系。方法:应用免疫组化Envision二步法,检测70例胃癌组织中HER-2和GST-π的表达情况,并结合其临床病理特点进行分析。结果:HER-2和GST-π在胃癌组织中的表达阳性率分别为27.1%(19/70)和58.6%(41/70)。阳性表达与肿瘤分化程度,侵袭深度,有无淋巴结转移及TNM分期有关(P<0.01,P<0.05),而与患者的性别及年龄、肿瘤部位和大小无关(P>0.05)。HER-2和GST-π两者之间在胃癌组织中的表达呈正相关(P<0.01)。结论:HER-2和GST-π的表达参与胃癌的生长、侵袭和转移过程。其联合检测有助于胃癌患者靶向药物和化疗药物的选择,也为胃癌的预后判断提供客观的参考指标。 Objective:To investigate the expressions of HER-2 and GST-πin human gastric carcinoma and to study the relationship with the clinicopathologic factors of gastric carcinoma.Methods: The Envision immunohistochemical stain method was used to detect HER-2 and GST-πprotein expressions in 70 sample of gastric carcinoma tissues.And their corresponding clinical data were analyzed retrospectively.Results: The positive expression rates of them were 27.1%(19/70) and 58.6%(41/70).The positive expression rates were closely related to the differentiation of the cancer,invasion depth,lymphatic metastasis and TNM(P0.01,P0.05),but not to the patient' s sex,age,tumor site and size(P0.05).There was a positive correlation between HER-2 and GST-π expressions in gastric cancer tissues.Conclusion: HER-2 and GST-π expressions participate in the development,invasion and metastasis process of gastric cancer.Combined detection of them can be looked as an important symbol for guiding the molecular targeting therapy and chemotherapy of gastric cancer,and judging the prognosis of gastric cancer.
出处 《现代肿瘤医学》 CAS 2012年第5期984-987,共4页 Journal of Modern Oncology
基金 四川省卫生厅科研项目(编号:00077)
关键词 胃癌 表皮生长因子受体-2 胎盘型谷胱甘肽-S-转移酶-π 免疫组织化学 gastric carcinoma HER-2 GST-π immunohistochemicalstry
  • 相关文献

参考文献2

二级参考文献4

共引文献26

同被引文献14

  • 1Bang YJ, Van Cutsem E,Feyereislova A,et al. Trastuzumab in com-bination with chemotherapy versus chemotherapy alone for treat-ment of HER2 - positive advanced gastric or gastro - oesophagealjunction cancer ( ToGA ) : a phase3 , open - label,randomised con-trolled trial[j]. Lancet,2010,376(9742) :687 -697.
  • 2Pinto C,Di Fabio F,Siena S,et al. Phase D study of cetuximab incombination with FOLFIRI in patients with untreated advanced gas-tric or gastroesophageal junction adenocarcinoma [ J]. Ann Oncol,2007,18(3):510- 517.
  • 3Abad A. New drugs in the treatment of gastric tumors[ J]. ClinTransl Oncol,2008,10(5) :256-261.
  • 4Han SW,Oh DY,Im SA,et al. Phase H study and biomarker anal-ysis of cetuximab combined with modified FOLFOX6 in advancedgastric cancer[ J]. Br J Cancer,2009,100(2) :298 -304.
  • 5Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer[J]. Oncology,2010,78(1) :26 -33.
  • 6Okines AF,Cunningham D. Trastuzumab in gastric cancer[ J]. EurJ Cancer,2010,46(11) :1949 -1959.
  • 7Sygiyama T,Yoshimoto T,Sato R,et al. Endothelin - 1 induces cy-clooxygenase - 2 expression and generation of reactive oxygen spe-cies in endothelial cells [ J]. J Cardiovase Pharmacol, 2004,44(l);S332 -335.
  • 8Kundu N,Walser TC,Ma X,et al. Cyclooxygenase inhibitors modu-late NK activities that control metastatic disease[ J] . Carcinoma Im-munol Immunother,2005 ,54( 10) :981 -987.
  • 9Sharma S,Zhu L,Yang SC,et al. Cyclooxygenase 2 inhibition pro-motes IFN 一 gamma - dependent enhancement of antitumor re-sponses[ J]. J Immunol 2005,175(2) :813 -819.
  • 10Rasmi Y, Allameh A,Nasseri - Moghaddam S,et al. Comparisonof glutathione S - transferase - Pi expression at mRNA levels inoesophageal mucosa using RT - PCR - ELISA in individuals withreflux diseases,adenocarcinoma and squamous cell carcinoma[J]. Clin Biochem,2006,39( 10) :997 - 1001.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部